Bharat Biotech: Study on Covishield, Covaxin antibody response is limited, Report Says

Bharat Biotech

The Hyderabad-based manufacturer of the COVID-19 Vaccine has said it will release the data from the testing stage on the 3rd of July. After that, it’s going to be in for to give any licenses to COVAXIN. 

New Delhi: Bharat Biotech, Hyderabad-based manufacturer of a COVID vaccine and the rejection of the latest work that claims to be Covaxin is far less effective against a variant of the B. 1.617.2, one of the tribe in the first instance, the responsibility for the violent ending of the initial wave of the pandemic. 

The company has also rejected the claim that its Covaxin is no more effective than an Institute of India (SII) Covishield. 

ALSO READ: ‘Feeling numb’: Indian Markets Continue to Rise as Traders Face Covid-19

“There have done many missteps in the past, similar statement of an evaluation of the immunogenicity in acknowledgment to the spike protein of the first plus second doses of the Indian Vaccine. The newspaper, which published a comparative report, said that the Covishield produce more antibodies than COVAXIN. This is a peer-reviewed publication in both statistical and scientific research. The Design and implementation of the research reflect the ad-hoc analysis, which is not pre-determined by speculation, ” the company said. 

 The Hyderabad-based manufacturer of the COVID-19 Vaccine has said it will release the data from the testing stage on the 3rd of July. After that, it’s going to be in for to give any licenses to COVAXIN. 

“It’s necessary to know, and I would like to repeat once again that the phase-3, the information will only be provided to the Centre of the Organisation for the improvement of living Standards (CDSCO), and then to peer-reviewed journals, with a 3-month publication period, and the reported results of the phase 3 COVAXIN a full trial, the information will be published in July. As soon as the data from the final analysis of Phase III clinical trials are available, Bharat Biotech will have to apply for a fully-licensed COVAXIN program, ” said one of the IMMEDIATE declaration of Bharat Biotech is on a Wednesday. 

When it comes to the Vaccine effectiveness, the company said: “the Vaccine’s effectiveness refers to the ability of the Vaccine to be one of the est a positive effect on the immune individuals is, as defined by the population under ideal conditions. When it comes to efficacy and safety, data about the effectiveness of the Covaxin, including its overall effect, is that of 78 percent, and the impact on hospital care, and is 100 percent. “

READ MORE: G7 Agreement on 15% Global Tax Rates for India: Experts

The organization declared,” the Vaccines inactivated among all of the diseases are one of the best in the safety of the symbols used in the system.” Several approved inactivated vaccines for polio, Japanese encephalitis, Rabies, hepatitis A and B, and several vaccines, like Chikungunya, Zika, Dengue fever, and polio. 

Recently, an expert in the research report on the effectiveness of the Vaccine, Bharat Biotech, said that it was experiencing and will continue to be subjected to the most intensive monitoring of the safety and efficacy of the history of the Indian Vaccine.

“Bharat Biotech is also conducting a Phase 4. The test is to check that the actual effectiveness of the vaccination and their vaccination meet all of the serious, scientific standards of safety, efficacy, and manufacturing quality that is required to support the operation of the emergency, in a resolution,” the company said.

You may be interested

Cyclone Akvan Strengthens Over the Bay of Bengal: Why Is Andhra Pradesh on High Alert
Environment
0 shares10 views
Environment
0 shares10 views

Cyclone Akvan Strengthens Over the Bay of Bengal: Why Is Andhra Pradesh on High Alert

Anshika Jain - Nov 18, 2026

Cyclone Akvan has intensified over the Bay of Bengal, putting coastal Andhra Pradesh and neighbouring regions on heightened alert. The developing weather system has raised concerns about…

Why Does a Strong US Dollar Sometimes Put Pressure on Indian Bullion Prices
Business
0 shares11 views
Business
0 shares11 views

Why Does a Strong US Dollar Sometimes Put Pressure on Indian Bullion Prices

Anshika Jain - Nov 18, 2026

The US dollar plays an important role in determining the direction of international commodity markets, including gold and silver. Although India has a strong domestic market for…

Can India’s Solar Industry Influence Long-Term Silver Demand
Artificial Intelligence
0 shares10 views
Artificial Intelligence
0 shares10 views

Can India’s Solar Industry Influence Long-Term Silver Demand

Anshika Jain - Nov 18, 2026

India's rapidly expanding solar industry is creating an important connection between renewable energy development and the global silver market. Silver is widely recognised as a precious metal…

Most from this category